Vertex Pharmaceuticals executive reports no VRTX stake

Vertex Pharmaceuticals reported Jasper van Grunsven, EVP, CP and NPPO, as an insider with no reportable holdings or transactions on his initial Form 3.

Rhea-AI Filing Summary

VERTEX PHARMACEUTICALS INC / MA (VRTX) filed an initial statement of beneficial ownership for Jasper van Grunsven, who serves as EVP, CP and NPPO. The Form 3 lists no reportable holdings or transactions in Vertex securities at the time of this filing. A Power of Attorney is noted as Exhibit 24.

Key Figures

Buy transactions: 0 Sell transactions: 0 Derivative positions: 0 +1 more

4 metrics

Buy transactions 0 Number of buy transactions reported for this Form 3

Sell transactions 0 Number of sell transactions reported for this Form 3

Derivative positions 0 Number of derivative transaction records and remaining derivative positions

Holding entries 0 Reported holding entries in non-derivative securities

Key Terms

Form 3, beneficial ownership, Power of Attorney, derivative positions

4 terms

Form 3 regulatory

"filed an initial statement of beneficial ownership for Jasper van Grunsven"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

beneficial ownership financial

"filed an initial statement of beneficial ownership for Jasper van Grunsven"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Power of Attorney regulatory

"A Power of Attorney is noted as Exhibit 24"

A power of attorney is a legal document that allows one person to make decisions and act on behalf of another person, often in financial or legal matters. It’s like giving someone a trusted helper or agent the authority to handle important tasks if you are unable to do so yourself. This matters to investors because it can impact how their assets are managed or transferred if they become unable to oversee their affairs.

derivative positions financial

"no derivative positions, indicating that no beneficial ownership"

Derivative positions are contracts that derive their value from an underlying asset—such as a stock, bond, currency or commodity—and include instruments like options, futures and swaps. Think of them as bets or insurance tied to an asset’s future price: they let investors amplify returns, hedge risk or take exposure without owning the asset directly, which can meaningfully increase potential gains, losses and volatility in a portfolio.

FAQ

What does the Form 3 filing for VRTX disclose about Jasper van Grunsven?

The Form 3 identifies Jasper van Grunsven as an insider of Vertex Pharmaceuticals, serving as EVP, CP and NPPO. It reports no transactions and no reportable holdings of Vertex securities at the time of the filing.

Are there any buy or sell transactions reported for VRTX in this Form 3?

No. The Form 3 for VRTX shows no buy or sell transactions, with all transaction-related counts, including buys, sells, exercises, and gifts, reported as zero in the transaction summary.

Does Jasper van Grunsven report any Vertex (VRTX) share ownership on this Form 3?

No. The filing’s summaries show no reportable holdings entries and no derivative positions, indicating that no beneficial ownership of VRTX securities is reported on this initial Form 3.

What position does Jasper van Grunsven hold at Vertex Pharmaceuticals (VRTX)?

Jasper van Grunsven is reported as an officer of Vertex Pharmaceuticals with the title EVP, CP and NPPO, as disclosed in the reporting person details of the Form 3.

What additional document is referenced in this VRTX Form 3 filing?

The remarks section references Exhibit 24 - Power of Attorney, indicating that a power of attorney document is associated with this Form 3 for Vertex Pharmaceuticals.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/10/2026 - 04:16 PM Accepted by SEC EDGAR 09/10/2026 - 04:16 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

van Grunsven Jasper

(Last) (First) (Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON MASSACHUSETTS 02110

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
09/08/2026

3. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, CP and NPPO

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Christiana Stevenson, Attorney-in-Fact	09/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)